[Intravitreal ranibizumab for diabetic macula edema].

25 patients with diabetic macula edema (DME) treated with 0,5 mg intravitreal ranibizumab (Lucentis) were studied. Mean number of intravitreal injections was 1.7 (1-5 injections). Visual acuity improved from 0.29 +/- 0.03 to 0.36 +/- 0.04 after the 1st injection and to 0.38 +/- 0.04 after the last one (p < 0.001). Central retinal thickness reduced from 469 +/- 36.3 to 353 +/- 31.5 microm in a month after the 1st injection and was 346 +/- 30.3 microm after the last one (p < 0.05). No systemic or ocular adverse effects were observed. Intravitreal ranibitumab (Lucentis) leads to stabilization and improvement of visual acuity and reduction of DME. The procedure is a safe treatment option for DME.